CCKBR and metabolic dysfunction-associated steatohepatitis: In fact, in [19] 35% of the mice on a NASH-inducing diet developed dysplastic nodules or HCC after 18 weeks, while none of the mice treated with a CCK-BR antagonist, proglumide, developed HCC.